Latest News
Research, Center News & Funding
Bernard Fuemmeler named Masseys associate director for cancer prevention and control
Jun 1, 2016
VCU Massey Cancer Center welcomes Bernard Fuemmeler, Ph.D., M.P.H., as the associate director for cancer prevention and control. A clinical health psychologist and epidemiologist, he joined the VCU School of Medicine as a professor in the Department of Health Behavior and Policy in June 2016.
As the associate director for cancer prevention and control (CPC) at Massey, Fuemmeler will serve on the cancer center’s Executive Committee and will develop and lead the strategic direction of CPC-related research at Massey. He will collaborate with health services and behavioral scientists as well as laboratory and clinical investigators of the cancer center’s various scientific programs to forge links that bridge the cancer center’s CPC, clinical and basic science. He will also focus on opportunities to increase the number of Massey’s CPC researchers, expand its areas of research interest and grow its funding base.
CPC research is research that studies the behavioral, environmental, organizational and policy factors that affect cancer risk, diagnosis, treatment and survival. CPC research at Massey is focused on the entire cancer continuum, from prevention to survivorship. Current Massey CPC research, for example, is focused on tobacco control and regulation, cancer health outcomes, decision making, screening and health disparities.
“We are very pleased to welcome Dr. Fuemmeler to Massey to direct our CPC research efforts,” said Gordon D. Ginder, M.D., director of VCU Massey Cancer Center. “He has the expertise, experience and creativity needed to help Massey foster collaborations that advance CPC science and ultimately improve lives.”
“I feel honored and fortunate to assume this leadership role and join Massey and the vibrant VCU community,” Fuemmeler said.
Fuemmeler studies the biological, behavioral and social determinants that contribute to the development of behavioral risks for cancer, such as obesity, smoking and physical inactivity. He has also led work aimed at improving the health of adolescent and young adult (AYA) cancer survivors. Much of his intervention-based research employs the use of digital technology (e.g., mobile phones apps, text messaging), to facilitate health promotion interventions, such as obesity prevention among AYA survivors or HPV vaccination among pre-adolescents.
“A primary goal of my research is to help identify what may be driving some of the key lifestyle risk factors for cancer with the intention of translating this knowledge to improve population health and reduce cancer risk,” Fuemmeler said.
The National Institutes of Health (NIH), the Lance Armstrong Foundation and the National Cancer Institute (NCI), among others, have funded Fuemmeler’s research. His study findings have been published in nearly 60 peer-reviewed scientific journals, including the American Journal of Preventive Medicine, Epigenetics, JAMA Psychiatry and the Journal of Pediatric Hematology and Oncology.
Fuemmeler currently serves as a standing member on an NIH study section on psychosocial risk and disease prevention and has been an ad hoc member on several other NIH study sections.
Prior to joining VCU, Fuemmeler held various professorial roles at Duke University for more than 10 years. His most recent position was associate professor of Community and Family Medicine with secondary faculty appointments in Psychiatry and Behavioral Sciences as well as Psychology and Neuroscience. He was also a member of the Duke University Comprehensive Cancer Institute and an affiliate of Duke’s Global Health Institute.
Fuemmeler received a bachelor’s degree in psychology/philosophy from the University of New Mexico, both an M.S. in psychology and a Ph.D. in clinical psychology from Oklahoma State University and an M.P.H. in quantitative methods from Harvard University. He completed a post-doctoral fellowship at NCI in the flagship cancer prevention fellowship training program.
Originally from Albuquerque, New Mexico, Fuemmeler moved to Durham, North Carolina, in 2005, where he met his wife. They have two young children.
Written by: Jenny Owen
Related News
Research, Center News & Funding
With new grant funding, researcher hopes to take down multiple drivers of lung cancer with a single strikeAug 08, 2024
Center News & Funding, Community Engagement & Health Equity, Clinical, Research, Prevention & Control
A journey of unrelenting hope and resilienceAug 05, 2024
Research, Center News & Funding
Massey trainee receives prestigious Susan G. Komen grantAug 05, 2024
Get access to new, innovative care
Treatments in clinical trials may be more effective or have fewer side effects than the treatments that are currently available. With more than 200 studies for multiple types of cancers and cancer prevention, Massey supports a wide array of clinical trials.
Find a provider
Massey supports hundreds of top cancer specialists serving the needs of our patients. Massey’s medical team provides a wealth of expertise in cancer diagnosis, treatment, prevention and symptom management.
Related News
Clinical, Center News & Funding
More than 50 Massey doctors named ‘Virginia’s Top Doctors’ by Virginia BusinessJan 10, 2025
Research, Clinical, Community Engagement & Health Equity, Center News & Funding
‘Because students’: Remembering Dani NoreikaDec 17, 2024
Get access to new, innovative care
Treatments in clinical trials may be more effective or have fewer side effects than the treatments that are currently available. With more than 200 studies for multiple types of cancers and cancer prevention, Massey supports a wide array of clinical trials.
Find a provider
Massey supports hundreds of top cancer specialists serving the needs of our patients. Massey’s medical team provides a wealth of expertise in cancer diagnosis, treatment, prevention and symptom management.
Latest News
Center News & Funding
VCU Massey researchers encouraged by Vice President Bidens $70 million Genomics Data Commons project
Jun 14, 2016
Researchers from Virginia Commonwealth University(VCU) Massey Cancer Center were in attendance at the American Society for Clinical Oncology’s annual meeting in Chicago when Vice President Joe Biden announced that more than $70 million would be invested in the development of the Genomics Data Commons (GDC), an information center housed at the University of Chicago and funded by the National Cancer Institute (NCI) to help facilitate the sharing of genomic and clinical data among cancer researchers in order to advance personalized medicine.
“We have been waiting for the launch of the Genomics Data Commons since last year when we first heard about it,” says Amy Olex, a bioinformatics specialist at VCU’s C. Kenneth and Dianne Wright Center for Clinical and Translational Research (CCTR). “With its implementation, cancer researchers at VCU will have seamless access to data from multiple cancer genomic projects.”
For the past two years, the CCTR has been helping VCU researchers access and analyze over 240 terabytes of DNA sequencing data from The Cancer Genome Atlas (TCGA) project, a collaborative effort supervised by the NCI that has sequenced more than 500 patient samples in order to catalog genetic mutations responsible for cancer. Information obtained through DNA sequencing helps scientists understand exactly what fuels cancer growth, and it has given rise to a new class of precision therapies designed to target cancer-causing mutations.
Data from TCGA will be transferred over to the GDC, along with data from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET), which is a pediatric version of TCGA. VCU has made significant investments in data storage and other bioinformatics infrastructure to help scientists analyze DNA sequencing data, and workshops are scheduled to help researchers make full use of the data available through the GDC.
“VCU is ahead of the curve in preparations to analyze DNA sequencing data, and I believe this will make us a valuable contributor to the GDC project,” says Krzysztof Cios, professor and chair of the Department for Computer Science and director of enterprise informatics at VCU. “These investments will also better prepare us for the storage and analysis of DNA sequencing information from our patients as Massey builds out its precision medicine capabilities.”
In 2014, Massey became the first cancer care provider in the state to perform advanced DNA sequencing for precision cancer treatment. At Massey, patients can have their DNA sequenced to determine whether they have mutations in dozens of genes that might respond to certain therapies. Massey researchers are also partnering with the NCI and other institutions on clinical trials testing targeted therapies not yet available to community practices. Data from these types of studies will eventually be fed into the GDC to facilitate collaboration and hopefully speed up discoveries.
Visit cctr.vcu.edu to learn more about resources available through the CCTR, and masseyprecisionmedicine.com to learn more about DNA sequencing at VCU Massey Cancer Center.
Written by: John Wallace
Related News
Clinical, Center News & Funding
More than 50 Massey doctors named ‘Virginia’s Top Doctors’ by Virginia BusinessJan 10, 2025
Research, Clinical, Community Engagement & Health Equity, Center News & Funding
‘Because students’: Remembering Dani NoreikaDec 17, 2024
Get access to new, innovative care
Treatments in clinical trials may be more effective or have fewer side effects than the treatments that are currently available. With more than 200 studies for multiple types of cancers and cancer prevention, Massey supports a wide array of clinical trials.
Find a provider
Massey supports hundreds of top cancer specialists serving the needs of our patients. Massey’s medical team provides a wealth of expertise in cancer diagnosis, treatment, prevention and symptom management.